FDA Bars Tyler Jordan Hall from Drug Imports After Conviction
Published Date: 1/23/2026
Notice
Summary
Tyler Jordan Hall is officially banned for 5 years from importing any drugs into the U.S. because he was convicted of bringing in unapproved drugs. He didn’t respond to the FDA’s notice, so the ban starts January 23, 2026, and he can apply to end it anytime. This means no drug imports from him for a while, keeping the market safer and cleaner!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Five-Year Import Ban on Named Importer
The FDA debarred Tyler Jordan Hall for 5 years, effective January 23, 2026, prohibiting him from importing or offering for import any drug into the United States. The order also makes importing any drug by, with the assistance of, or at the direction of Mr. Hall a prohibited act.
Right to Apply to End Debarment Anytime
Mr. Hall may apply at any time to terminate his debarment under section 306(d)(1) of the FD&C Act. Applications may be submitted electronically at https://www.regulations.gov (Docket No. FDA-2025-N-1331) or as written/paper submissions to the Dockets Management Staff with options to mark confidential information as described in the order.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12445 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Traction Device
The FDA is officially putting the endoscopic traction device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while making it easier for patients to get access to this cool medical tool. The new rules took effect on June 22, 2026, and could speed up innovation without extra costs for makers.
2026-12444 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Light-Projecting Measuring Device
The FDA is officially putting the endoscopic light-projecting measuring device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while speeding up patient access to cool new tech. The new rules took effect June 22, 2026, and could save time and money for makers and users alike.
2026-12367 — Epizyme, Inc.; Withdrawal of Approval of New Drug Application for TAZVERIK (Tazemetostat) Tablet, 200 Milligrams
Epizyme, Inc. has asked the FDA to withdraw approval for their cancer drug TAZVERIK (200 mg tablets), effective June 22, 2026. This means TAZVERIK will no longer be officially approved for treating certain sarcomas and lymphomas, affecting patients and healthcare providers relying on it. The change might impact treatment options and insurance coverage, so folks should check with their doctors about next steps.
2026-12443 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple In Vitro Diagnostic Device for the Detection of Secreted Proteins From Bacillus Species (spp.) in Human Clinical Samples
The FDA is officially putting a simple test that spots proteins from Bacillus bacteria in human samples into a safer, easier-to-manage category called Class II. This change helps make sure the test is safe and works well while speeding up patient access to cool new medical tools. The new rules kicked in on June 22, 2026, but have been in effect since February 3, 2023, making life simpler for device makers and patients alike.
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
2026-12237 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Regulations for Type A Medicated Articles and Medicated Feeds
The FDA is updating how companies that make special animal medicines and feeds keep their records and follow quality rules. This affects manufacturers of Type A medicated articles and medicated feeds, helping ensure safe and reliable products for animals. Comments on these changes are open until July 20, 2026, and the updates aim to keep things clear without adding extra costs.
Previous / Next Documents
Previous: 2026-01295 — Agency Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; Regional Economic Development Data Collection Instrument
The Department of Commerce wants your thoughts on a new survey that helps track how regions grow their economies. This affects communities and businesses that work with the Economic Development Administration, and your feedback is needed by March 24, 2026. The goal is to keep the survey helpful but easy to fill out, with no extra costs for participants.
Next: 2026-01297 — Application for Authorization To Export Electric Energy; Electric Power Markets USA, LLC
Electric Power Markets USA, LLC wants permission to send electricity from the U.S. to Mexico for the next five years. This affects energy buyers and sellers in Texas and could boost cross-border power trade without hurting U.S. electricity supplies. If you have thoughts or concerns, you’ve got until February 23, 2026, to speak up!